Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push
[ad_1] David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC Eli Lilly on Tuesday said it struck a $2.4 billion deal to acquire Dice Therapeutics in a bid to bulk up its treatment portfolio for immune-related diseases. Eli Lilly will pay $48 per share in cash to buy Dice, representing around a 40% premium to…